AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00795288
Drug: Simvastatin, 80 mg/day for 21 days
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment group
Trial: NCT00795288
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group
Trial: NCT00748956
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo comparator (0nmol)) administered intranasally
Trial: NCT01831817
Drug: 5% calcium sodium phosphosilicate/ sodium monofluorophosphate dentifrice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium sodium phosphosilicate dentifrice (5% w/w) and 1500 ppm F as sodium monofluorophosphate
Trial: NCT01831817
Drug: 0% calcium sodium phosphosilicate/ sodium monofluorophosphate dentifrice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No calcium sodium phosphosilicate and 1500 ppm F as sodium monofluorophosphate
Trial: NCT02845531
Drug: Optimal Medical Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02495454
Drug: Ga101
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01524081
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of saline infusion (Natrii chloridum: 9,0 g/l) 60 minutes prior the surgery~1. - 100ml saline solution~2. - 500ml saline solution
Trial: NCT01524081
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of saline infusion (Natrii chloridum: 9,0 g/l) 60 minutes prior the surgery~1. - 2x 100ml saline solution~2. - 500ml saline solution
Trial: NCT02193594
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Within 2 months after surgery,the patients will receive chemotherapy for 6 to 8 cycles ,consist of oxaliplatin 130mg/m2 administrated on day1 and S-1® 40-60mg twice per day on days 1 to 14 per 3 weeks.The S-1® dosage depends on the patient BSA(BSA\<1.25m2 40mg,1.25 m2≤BSA≤1.5 m2 50mg ,BSA\>1.5 m2 60mg). Patients in the CCRT group will receive 6 cycles of chemotherapy and patients in the CT group will receive 8 cycles of chemotherapy.
Trial: NCT00006184
Drug: Myeloma Immunoglobulin Idiotype Vaccine
RxNorm normalized name: vaccinia immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 subcutaneous (SC) injections of myeloma protein within 10 weeks before stem cell collection the first (week 0), second (week 2), and third injection (week 6) with Id-KLH (0.5 mg SC day 1)
Trial: NCT00491374
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Nasal Spray 4 sprays once daily every morning for 28 days.
Trial: NCT00006184
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Induction chemotherapy: 600 mg/m\^2 day 4 Transplant: 1200 mg/m\^2 intravenous x 4 days (days -6, -5, -4, -3)
Trial: NCT00006184
Drug: Doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy: 10 mg/m\^2 day continuous intravenous (CIV) days 1-3
Trial: NCT00006184
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Transplant: 5 mg/m\^2 intravenous on days +1, +3, +6, +11
Trial: NCT00094432
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets, Oral, 0 mg, Once daily, 8 weeks.
Trial: NCT01493856
Drug: DWJ1276
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablet, Rosuvastatin 20mg and olmesartan medoxomil 40mg
Trial: NCT00835497
Drug: 5 mg/500 mg METAGLIP™ Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 x 5 mg/500 mg, single-dose fasting
Trial: NCT04065919
Drug: 0.25% Bupivacaine with epinephrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25% Bupivacaine with epinephrine at 1cc/kg total dose infiltrated into 5th intercostal space
Trial: NCT03000036
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients had prescribed endovenous doxorubicin as part of their chemotherapy regimen (mean cumulative dose 102,66 mg/m2, administered in 4 doses with 21 days interval).
Trial: NCT00537420
Drug: Nasal Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal placebo, three times a day, 30 minutes before a meal for 24 weeks.
Trial: NCT00537420
Drug: Placebo Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules will be taken once daily with or without food.
Trial: NCT00259558
Drug: retarded release phosphatidylcholine
RxNorm normalized name: phosphatidylcholine, soybean
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02262754
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for PF-06372865 and placebo for naproxen daily
Trial: NCT02262754
Drug: Naproxen
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 500 mg BID for 4 weeks
Trial: NCT02281136
Drug: Aminolevulinic Acid (ALA)
DrugBank: Aminolevulinic acid (DB00855)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20% ALA applied to upper extremities for 3 hours prior to 10 J/cm2 blue light
Trial: NCT01825408
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects with CRSwNP who are not allergic to doxycycline will receive Doxycycline 100mg BID for either 3 or 6 weeks duration.
Trial: NCT01825408
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subjects with CRS without Nasal Polyposis (CRSwNP)who are not allergic to azithromycin will be given Azithromycin 250mg daily for either 3 or 6 weeks duration.
Trial: NCT00317408
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00317408
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00317408
Drug: prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00012051
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002961
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Arms A and B Day 2 and 3: Cyclophosphamide 60 mg/kg intravenously; Administer 20 mg/ml concentration over 2 hours.
Trial: NCT00176293
Drug: doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin 50mg/m\^2 I.V. on day 5
Trial: NCT03212625
Drug: Urea Cream 20%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorafenib 400mg (twice daily), Spread urea cream (urea 20%)
Trial: NCT03212625
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorafenib 400mg (twice daily), Spread placebo cream (urea 0%)
Trial: NCT00482079
Drug: Comparator: placebo (unspecified) / Duration of Treatment: 21 Weeks
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00002961
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: methotrexate 15 mg/m2 IV on day +1 (do not give until 24 hours after marrow infusion), and 10mg/mg2 IV on days +3 and +6.~Methotrexate may be held after two doses for bilirubin .2 mg/dL. If serum creatinine is \>2x baseline, methotrexate will be omitted. If the presence of ascites or pleural effusion, methotrexate will be omitted.
Trial: NCT04521491
Drug: FOLFOX4(infusional fluorouracil [FU], leucovorin [LV], and oxaliplatin [OXA]).
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFOX4 (OXA 85 mg/m2 intravenously \[IV\] on day 1; LV 200 mg/m2 IV from hour 0 to 2 on days 1 and 2; and FU 400 mg/m2 IV bolus at hour 2, then 600 mg/m2 over 22 hours on days 1 and 2, once every 2 weeks.All patients in the treatment group will receive FOLFOX4 at most 12 times beginning from the 4th week after liver resection.
Trial: NCT00799617
Drug: AndroGel® (testosterone gel)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone levels will be measured at regular intervals in order to achieve a testosterone level in the desired range.
Trial: NCT00799617
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone levels will be measured at regular intervals.
Trial: NCT03385239
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterile Normal Saline (0.9% NaCl).
Trial: NCT02667938
Drug: HCP1303 capsule 5/0.2mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02086422
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02667938
Drug: HCP1303 capsule 5/0.4mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02945644
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: take at bedtime for 14 days
Trial: NCT03281304
Drug: CP-690,500 5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CP-690,550 5 mg tablet BID
Trial: NCT03281304
Drug: CP-690,550 10 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CP-690,550 10 mg tablet BID
Trial: NCT02667938
Drug: HGP1201
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02648672
Drug: BPN14770
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BPN14770 is an investigational new drug being developed for the treatment of Alzheimer's disease and other cognitive disorders. BPN14770 is a small molecule, subtype selective, negative allosteric modulator of phosphodiesterase 4D.
Trial: NCT02648672
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03878303
Drug: AC0058TA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg capsules
Trial: NCT03878303
Drug: Placebo AC0058TA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: equivalent dose of investigational product
Trial: NCT02789592
Drug: Melatonin PR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For experimental treatment of RBD
Trial: NCT01478165
Drug: Total intravenous anesthesia
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total intravenous anesthesia plus normal saline 1.5 ml immediately before induction of anesthesia
Trial: NCT02667938
Drug: HCP1303 capsule 5/0.2mg placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02789592
Drug: Melatonin PR placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pill manufactured to mask melatonin PR 2mg tablet
Trial: NCT02667938
Drug: HCP1303 capsule 5/0.4mg placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02188186
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventioanl treament with dose escalation
Trial: NCT02667938
Drug: HGP1201 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04495088
Drug: mFOLFOX (neoadjuvant)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: neoadjuvant application Folinic acid: 400 mg/m2, 2h i.v., on day 1 Oxaliplatin: 85 mg/m2, 2-6h i.v., on day 1 5-FU: 2400 mg/m2, 46-48h i.v., on day 1. Cycles are repeated on day 15. A total of 6 cycles are administered.
Trial: NCT04495088
Drug: XELOX (neoadjuvant)
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: neoadjuvant application Capecitabine: 1,000 mg/m2 bid, po, on days 1-14 Oxaliplatin: 130 mg/m2, 2-6h i.v. day 1 Cycles are repeated on day 22. A total of 4 cycles are administered.
Trial: NCT04495088
Drug: mFOLFOX (adjuvant)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: adjuvant application Folinic acid: 400 mg/m2, 2h i.v., on day 1 Oxaliplatin: 85 mg/m2, 2-6h i.v., on day 1 5-FU: 2400 mg/m2, 46-48h i.v., on day 1. Cycles are repeated on day 15. A total of 6 cycles are administered.
Trial: NCT04495088
Drug: XELOX (adjuvant)
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: adjuvant application Capecitabine: 1,000 mg/m2 bid, po, on days 1-14 Oxaliplatin: 130 mg/m2, 2-6h i.v. day 1 Cycles are repeated on day 22. A total of 4 cycles are administered.
Trial: NCT04495088
Drug: Capecitabine (adjuvant)
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: adjuvant application Capecitabine: 1,250 mg/m2 bid, po, on days 1-14 Cycles are repeated on day 22. A total of 8 cycles are administered.
Trial: NCT04495088
Drug: infusional 5-FU/FA AIO regimen (adjuvant)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: adjuvant application Folinic acid 2h i.v. 500 mg/m² 5-FU 2,600mg/m² (24h infusion) Days 1, 8, 15, 22, 29, 36; cycle is repeated day 57 (representing one cycle); a total of 3 cycles should be administered.
Trial: NCT04495088
Drug: infusional 5-FU/FA de Gramont (adjuvant)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: adjuvant application Folinic acid 2h i.v. 200 mg/m² days 1 and 2 5-FU 400mg/m² bolus followed by 600mg/m² 22h infusion days 1 and 2 The cycle is repeated day 15; a total of 12 cycles should be administered.
Trial: NCT03657472
Drug: CJ-30061
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Test: CJ-30061(Fixed-dose combination drug containing Amlodipine 5mg/Valsartan 160mg/Atorvastatin 20mg)
Trial: NCT03657472
Drug: Exforge® 5/160mg & Lipitor® 20mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference: Co-administration of Exforge® tab 5/160mg and Lipitor® tab 20mg
Trial: NCT00970606
Drug: Rosuvastatin (crestor)
RxNorm normalized name: rosuvastatin Oral Tablet [Crestor]
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 20 mg tablets once daily x max 28 days or for an additional 3 days following ICU discharge
Trial: NCT00970606
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet identical to active therapy. 1 tablet per day
Trial: NCT04426695
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo IV Single Dose
Trial: NCT04562155
Drug: BAY1817080
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study drug BAY1817080 will be administered orally as tablet.
Trial: NCT04562155
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo for BAY1817080 will be administered orally as tablet.
Trial: NCT03787992
Drug: Placebo AST2818 80mg//40 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The initial dose of Placebo AST2818 80 mg once daily can be reduced to Placebo AST2818 40 mg once daily under specific circumstances. A cycle of treatment is defined as 21 days of once daily treatment. Number of cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
Trial: NCT00694980
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous and subcutaneous escalating doses
Trial: NCT00816868
Drug: erlotinib in combination with capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Erlotinib 150 mg Q.D. orally for 21 days plus Capecitabine 1000 mg/m2 twice daily for 2 weeks followed by 1 week break every 21 days Until PD, unacceptable toxicity or death.
Trial: NCT00955266
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline, 50cc delivered over 5 minutes
Trial: NCT04317248
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous drip，250mg/m\^2 per time，two days before each times of MSDCV therapy，total 6 times, in order to improve the immunosuppressive microenvironment of tumor，reduce CD4+CD25+FOXP3+regulatory T cells (Tregs）
Trial: NCT03317119
Drug: Trifluridine and Tipiracil Hydrochloride
RxNorm normalized name: tipiracil / trifluridine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT04473651
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo - capsules, orally (Part A only)
Trial: NCT01640730
Drug: Kanglaite Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30gm IV infusion 5 days a week for 3 weeks every 28 days
Trial: NCT03407872
Drug: Placebo DPI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive different cycle of treatment consisting of 4 dosing sequences administered within 2 weeks. Participants in this part will be randomized to receive Esketamine DPI or placebo in 3:1 ratio.~In each cohort, number of placebo inhalations within a dosing sequence will correspond to number of Esketamine DPI inhalations.
Trial: NCT02174653
Drug: EPs® 7630
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg EPs® 7630 film-coated tablets during 4 months Orally intake three times a day (in the morning, midday and evening)
Trial: NCT02174653
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control: Placebo film coated tablets during 4 months Orally intake three times a day (in the morning, midday and evening)
Trial: NCT01820052
Drug: Oral Iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 230 mg of elemental oral iron tablets will be administered daily for 3 months
Trial: NCT01820052
Drug: Oral Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablets matching oral iron will be administered daily for 3 months
Trial: NCT01813318
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects receiving placebo will be dosed similarly to the acamprosate group.
Trial: NCT03641352
Drug: CKD-501 0.5mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CKD-501 0.5mg, orally, 1 tablet once a dqy for 24weeks or 52weeks (if extension study) with D150 and D759
Trial: NCT03641352
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, orally, 1 tablet once a dqy for 24weeks or 52weeks (if extension study) with D150 and D759. CKD-501 placebo will be changed to CKD-501 from extension study to EOS(end of study).
Trial: NCT00734071
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vortioxetine placebo-matching capsules
Trial: NCT03143751
Drug: NaCl20% (Continuous hyperosmolar therapy)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early intravenous administration (\<24 hours after traumatic brain injury) of NaCl20% for a minimal duration of 48 hours (continued for as long as is necessary to prevent intracranial hypertension)~1-hour bolus (15 g if Na+ \< 145 mmol/L; 7.5 g if 145 \< Na+ \< 150 mmol/L; or no bolus) followed by 1 g/hour as long as Na+\< 150 mmol/L, reduced to 0.5 g/L if 150 \< Na+ \< 155 mmol/L, Discontinuation when 155 mmol/L\<Na+
Trial: NCT00505947
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo 5 mg/Kg body weight by intravenous infusion
Trial: NCT00053807
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02045693
Drug: DCV 3DAA FDC
RxNorm normalized name: DYE FDC BLUE #1
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00649831
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin 250 mg tablet; take 2 tablets by mouth on the first day, then 1 tablet by mouth from Days 2 to 5
Trial: NCT01650740
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: small placebo capsule (30 mg duloxetine equivalent) x 1 week followed by 60 mg equivalent capsule daily
Trial: NCT01679002
Drug: BIA 2-093
RxNorm normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01679002
Drug: Oxcarbazepine
RxNorm normalized name: Oxcarbazepine
DrugBank: Oxcarbazepine (DB00776)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02442258
Drug: ABT-493
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of ABT-493 will be given orally in combination with ABT-530.
Trial: NCT02442258
Drug: ABT-530
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of ABT-530 will be given orally in combination with ABT-493.
Trial: NCT01350089
Drug: Comparator 1 (with alcohol; without caffeine and energy drink)
RxNorm normalized name: Acetaminophen and Caffeine Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixture of 46.5 g ethanol (inform of vodka (37.5%)), (carbonated) water 250 mL, artificial fruit juice (21 g/L prepared with (carbonated) water). The final volume of the mixture 500 mL.
Trial: NCT01350089
Drug: Comparator 3 (with alcohol and energy drink)
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mixture of 46.5 g ethanol (inform of vodka (37.5%)), Red Bull® Energy Drink (250 mL, without flavour mixture to optimize blinding), artificial fruit juice (21 g/L prepared with (carbonated) water).The final volume of the mixture is 500 mL.
Trial: NCT02552303
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for Nuvigil (armodafinil)
Trial: NCT04534842
Drug: SYNB1618
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15-day dose-ramp regimen (4 dose levels) of orally administered SYNB1618
Trial: NCT04524403
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for once-daily oral dosing
Trial: NCT00820404
Drug: BLI-489
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00820404
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03731260
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet